摘要
糖尿病肾病是糖尿病患者常见的微血管并发症之一,也是引起终末期肾病的主要原因。二肽基肽酶4(DPP-4)抑制剂是一种新型降糖药,不仅降低血糖,还对糖尿病肾病有保护作用。DPP-4抑制剂可通过升高内源性胰高血糖素样肽-1(GLP-1)的水平,改善机体高血糖状态,减少白蛋白尿,降低血压,延缓糖尿病肾病的进展,并且还能调节非GLP-1底物的表达,发挥肾脏保护作用。对DPP-4抑制剂的研究,为糖尿病及其并发症的治疗提供了新的方向。
Diabetic nephropathy is one of the common microvascular complications of diabetes, also is the main cause of end-stage renal disease. Dipeptidyl peptidase-4（DPP-4） inhibitors are new drugs for treatment of diabetes,which not only lower blood sugar,but also has protective effect on diabetic nephropathy. Through increasing the endogenous glucagon-like peptide-1（GLP-1） levels,DPP-4 inhibitors improve the body＇s blood sugar,reduce albuminuria,lower blood pressure and slow the progress of diabetic nephropathy. And DPP-4 inhibitors have renal protective effect independent of GLP-1 through influencing the expression of other DPP-4 substrates. The study of DPP-4 inhibitors offers a new direction for the treatment of diabetes and its complications.
出处
《中国现代医生》
2016年第6期155-159,共5页
China Modern Doctor
